Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Small-cell lung cancer in the era of immunotherapy.

Literature DB >> 29299415

Small-cell lung cancer in the era of immunotherapy.

Margarita Majem¹, Charles M Rudin².

Abstract

Entities: Disease

Year: 2017 PMID： 29299415 PMCID： PMC5750148 DOI： 10.21037/tlcr.2017.10.06

Source DB: PubMed Journal: Transl Lung Cancer Res ISSN： 2218-6751

× No keyword cloud information.

17 in total

1. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma.

Authors: P Maddison; J Newsom-Davis; K R Mills; R L Souhami
Journal: Lancet Date: 1999-01-09 Impact factor: 79.321

2. Tumor immunotherapy directed at PD-1.

Authors: Antoni Ribas
Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245

3. PD-L1 expression in small cell neuroendocrine carcinomas.

Authors: Anne M Schultheis; Andreas H Scheel; Luka Ozretić; Julie George; Roman K Thomas; Thorsten Hagemann; Thomas Zander; Jürgen Wolf; Reinhard Buettner
Journal: Eur J Cancer Date: 2015-01-09 Impact factor: 9.162

4. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer.

Authors: Hidenobu Ishii; Koichi Azuma; Akihiko Kawahara; Kazuhiko Yamada; Yohei Imamura; Takaaki Tokito; Takashi Kinoshita; Masayoshi Kage; Tomoaki Hoshino
Journal: J Thorac Oncol Date: 2015-03 Impact factor: 15.609

5. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

Authors: Mary E R O'Brien; Tudor-Eliade Ciuleanu; Hristo Tsekov; Yaroslav Shparyk; Branka Cuceviá; Gabor Juhasz; Nicholas Thatcher; Graham A Ross; Graham C Dane; Theresa Crofts
Journal: J Clin Oncol Date: 2006-12-01 Impact factor: 44.544

6. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors: Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal: Science Date: 2015-03-12 Impact factor: 47.728

7. Paraneoplastic neurological autoimmunity and survival in small-cell lung cancer.

Authors: Paul Maddison; Bethan Lang
Journal: J Neuroimmunol Date: 2008-07-29 Impact factor: 3.478

8. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

Authors: J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray
Journal: Eur J Cancer Date: 2013-02-26 Impact factor: 9.162

9. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

Authors: Martin Reck; Alexander Luft; Aleksandra Szczesna; Libor Havel; Sang-We Kim; Wallace Akerley; Maria Catherine Pietanza; Yi-Long Wu; Christoph Zielinski; Michael Thomas; Enriqueta Felip; Kathryn Gold; Leora Horn; Joachim Aerts; Kazuhiko Nakagawa; Paul Lorigan; Anne Pieters; Teresa Kong Sanchez; Justin Fairchild; David Spigel
Journal: J Clin Oncol Date: 2016-11-01 Impact factor: 44.544

10. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Authors: Jedd D Wolchok; Vanna Chiarion-Sileni; Rene Gonzalez; Piotr Rutkowski; Jean-Jacques Grob; C Lance Cowey; Christopher D Lao; John Wagstaff; Dirk Schadendorf; Pier F Ferrucci; Michael Smylie; Reinhard Dummer; Andrew Hill; David Hogg; John Haanen; Matteo S Carlino; Oliver Bechter; Michele Maio; Ivan Marquez-Rodas; Massimo Guidoboni; Grant McArthur; Celeste Lebbé; Paolo A Ascierto; Georgina V Long; Jonathan Cebon; Jeffrey Sosman; Michael A Postow; Margaret K Callahan; Dana Walker; Linda Rollin; Rafia Bhore; F Stephen Hodi; James Larkin
Journal: N Engl J Med Date: 2017-09-11 Impact factor: 91.245

3 in total

1. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.

Authors: Triparna Sen; B Leticia Rodriguez; Limo Chen; Carminia M Della Corte; Naoto Morikawa; Junya Fujimoto; Sandra Cristea; Thuyen Nguyen; Lixia Diao; Lerong Li; Youhong Fan; Yongbin Yang; Jing Wang; Bonnie S Glisson; Ignacio I Wistuba; Julien Sage; John V Heymach; Don L Gibbons; Lauren A Byers
Journal: Cancer Discov Date: 2019-02-18 Impact factor: 39.397

Review 2. [Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].

Authors: Di Zhang; Jiaqi Huang; Chufeng Zhang; Yan Guan; Qisen Guo
Journal: Zhongguo Fei Ai Za Zhi Date: 2019-06-20

3. A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes.

Authors: Liang Wang; Bryan A Smith; Nikolas G Balanis; Brandon L Tsai; Kim Nguyen; Michael W Cheng; Matthew B Obusan; Favour N Esedebe; Saahil J Patel; Hanwei Zhang; Peter M Clark; Anthony E Sisk; Jonathan W Said; Jiaoti Huang; Thomas G Graeber; Owen N Witte; Arnold I Chin; Jung Wook Park
Journal: Proc Natl Acad Sci U S A Date: 2019-12-23 Impact factor: 11.205

3 in total